[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342637-105":59,"doc-detail-342637-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","proteomic-profiling-reveals-that-esr1-mutations-enhance-cyclin-dependent-kinase-signaling","Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling","","Breast cancers frequently express the estrogen receptor ESR1, a key driver of tumor growth and an established endocrine-therapy target. ESR1 mutations are linked to resistance to aromatase inhibitors by promoting ligand-independent receptor activity and reshaping signaling networks, yet protein-level changes remain insufficiently characterized. Integrated mass spectrometry proteomics compared protein and phosphoprotein states in breast cancer cell lines expressing Y537N and Y537S ESR1 mutations, revealing enrichment of mitotic and immune signaling, elevated proliferation-associated kinase activity (CDKs and mTOR), and pathway-dependent differences in motility versus proliferation across mutant and wild-type cells.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/proteomic-profiling-reveals-that-esr1-mutations-enhance-cyclin-dependent-kinase-signaling/342637/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/proteomic-profiling-reveals-that-esr1-mutations-enhance-cyclin-dependent-kinase-signaling/342637.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does this proteomic study address about ESR1 mutations?","Question",{"text":112,"@type":113},"It tests how ESR1 mutations alter protein and phosphoprotein landscapes in breast cancer models, beyond what genetic and transcriptomic analyses have already shown.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were ESR1 mutant cell models generated or defined in the study?",{"text":117,"@type":113},"The work profiles breast cancer cell lines expressing the frequent ESR1 mutations Y537N and Y537S, enabling direct comparison with wild-type ER cells.",{"name":119,"@type":110,"acceptedAnswer":120},"Which signaling pathways were enriched in ESR1 mutant cells?",{"text":121,"@type":113},"Global proteome analysis showed enrichment of mitotic and immune signaling pathways, while phosphoprotein analysis highlighted increased activity of proliferation-associated kinases, especially CDKs and mTOR.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342637,1790493738,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nProteomic profiling reveals that ESR1 mutations enhance cyclin‑dependent kinase signaling  \nTommaso De Marchi1*, Chun‑Fui Lai2, Georgia M. Simmons2, Isabella Goldsbrough2, Alison Harrod2, Thai Lam1, Lakjaya Buluwela2, Sven Kjellström 3,4, Christian Brueffer 5, Lao H. Saal 5, Johan Malmström6, SimakAli2* & Emma Niméus1,7*  \nThree quarters of all breast cancers express the estrogen receptor (ER, ESR1 gene), which promotes tumor growth and constitutes a direct target for endocrine therapies. ESR1 mutations have been implicated in therapy resistance in metastatic breast cancer, in particular to aromatase inhibitors. ESR1 mutations promote constitutive ER activity and affect other signaling pathways, allowing cancer cells to proliferate by employing mechanisms within and without direct regulation by the  \nER. Although subjected to extensive genetic and transcriptomic analyses, understanding of protein alterations remains poorly investigated. Towards this, we employed an integrated mass spectrometry based proteomic approach to profile the protein and phosphoprotein differences in breast cancer cell lines expressing the frequent Y537N andY537S ER mutations. Global proteome analysis revealed enrichment of mitotic and immune signaling pathways in ER mutant cells, while phosphoprotein analysis evidenced enriched activity of proliferation associated kinases, in particular CDKs and mTOR. Integration of protein expression and phosphorylation data revealed pathway‑dependent discrepancies (motility vs proliferation) that were observed at varying degrees across mutant and wt ER cells. Additionally, protein expression and phosphorylation patterns, while under different regulation, still recapitulated the estrogen‑independent phenotype of ER mutant cells. Our study is the first proteome‑centric characterization of ESR1 mutant models, out of which we confirm estrogen independence of ER mutants and reveal the enrichment of immune signaling pathways atthe proteomic level.  \nMost breast cancers express the estrogen receptor (ER; ESR1 gene), a steroid hormone receptor that acts as a transcription factor once bound by estrogens. ER positive breast cancers are treated with endocrine agents, which either block or degrade the receptor, or reduce systemic estrogen levels (aromatase inhibitors, AI)1,2.  \nAbout 30% of patients with ER-positive breast cancer treated with endocrine therapies develop recurrent disease, which is often refractory to further endocrine treatments. Several mechanisms of endocrine therapy resistance have been identified, such as alterations in expression of ER co-activators (e.g. AIB1/SRC-3)3, augmentation of other signaling pathways (e.g. ERK/MAPK)4, or the expression of mutant ERs5–7.  \nESR1 mutations have been reported in 11–55% of metastatic ER-positive breast cancers, mostly within the ligand-binding domain of the receptor (e.g. Y537N/C/S and D538G), and promote constitutive and ligandindependent activation ofthe ER8. On top of this, ESR1 mutations have been shown to activate other signaling pathways (e.g. interferon response)5,9–11, suggesting additional transcriptional effects when compared to the wt receptor (reviewed in12, 13). The genetic and transcriptomic alterations associated with expression of ER mutants have been widely investigated in breast cancer cell lines in which ER mutants arise spontaneously14, following ectopic expression5,6,8 or by CRISPR-Cas9-directed knock-in mutagenesis of the endogenous ESR1 gene9, 10, 15, 16.  \n1Division of Surgery, Oncology, and Pathology, Department of Clinical Sciences, Lund University, Solvegatan 19, 22362 Lund, Sweden. 2Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK. 3Department of Biochemistry and Structural Biology, Center for Molecular Protein Science, Lund University, Solvegatan 19, 22362 Lund, Sweden. 4Swedish National Infr","cbCaimbzjUWDWSXq","https://ap.wps.com/l/cbCaimbzjUWDWSXq","pdf",4963391,16,"English","# Integrated proteomic and phosphoproteomic strategy\n## Protein abundance differences in ESR1 mutant models\n## Phosphoprotein signaling and kinase activity\n## Pathway-level integration and phenotype recapitulation\n## Study rationale and background on endocrine resistance","[{\"question\":\"What question does this proteomic study address about ESR1 mutations?\",\"answer\":\"It tests how ESR1 mutations alter protein and phosphoprotein landscapes in breast cancer models, beyond what genetic and transcriptomic analyses have already shown.\"},{\"question\":\"How were ESR1 mutant cell models generated or defined in the study?\",\"answer\":\"The work profiles breast cancer cell lines expressing the frequent ESR1 mutations Y537N and Y537S, enabling direct comparison with wild-type ER cells.\"},{\"question\":\"Which signaling pathways were enriched in ESR1 mutant cells?\",\"answer\":\"Global proteome analysis showed enrichment of mitotic and immune signaling pathways, while phosphoprotein analysis highlighted increased activity of proliferation-associated kinases, especially CDKs and mTOR.\"}]","Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling | PDF",1790047513,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e98ed5d43e669b95a95b70d1feb3c401.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ba0da5e464e52fc3d487f581317c1dd.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e57947da613007f7365e2c66668f618a.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68713686ffc018fa10f43a66b2455403.webp",980,1287]